Elementis PLC reported full-year 2025 results that beat analyst expectations, driven by strong margin expansion despite challenging market conditions. The specialty chemicals company posted adjusted earnings per share of 13.7 cents, exceeding the consensus of 13.0 cents. Revenue declined 1.9% on a constant currency basis to $597.5m, slightly below the $601m consensus but up from $603.8m in 2024. Adjusted operating profit rose 4.6% to $126.7m, meeting estimates, while adjusted operating margin expanded 150 basis points to 21.2%. Personal Care revenue grew 2.4% to $224.5m with a surging margin of 32.4%. Coatings revenue fell 4.3% to $373.0m but maintained a resilient margin of 18.9%. The company announced the sale of its pharmaceutical manufacturing business to Associated British Foods (ABF) for an enterprise value of approximately €34m ($40m), expected to complete in Q2 2026 subject to regulatory approvals. This move sharpens Elementis's focus on Personal Care and Coatings markets.

Elementis expects to return the net cash proceeds to shareholders. The Board proposed a final dividend of 3.0 cents per share, raising the full-year dividend to 4.3 cents. The company also completed a £40.0m ($53.8m) share buyback program. Net debt increased to $185.4m from $157.2m, with the net debt to EBITDA ratio at 1.3x. Elementis delivered $18m in cost savings in 2025 and remains on track to deliver the remaining $4m in 2026. CEO Luc van Ravenstein stated the company delivered a 'resilient performance with strong growth in profitability and margins' despite the challenging environment. The strategic sale of the pharma unit marks a significant shift for Elementis.

The sale represents a strategic pivot for Elementis, shedding a non-core pharmaceutical manufacturing business to concentrate resources on its core Personal Care and Coatings segments. This move, combined with the strong margin performance across its remaining businesses, signals a focus on higher-margin areas. The transaction value of €34m ($40m) is modest, reflecting the nature of the divested unit, but the strategic benefits of simplification and focus are key. Returning proceeds to shareholders and maintaining a disciplined cost structure support the company's financial health and shareholder returns outlook.